H.C. Wainwright & Co., LLC’s Post

🔍 Feeling out of tune with your portfolio planning? Caroline Dewing Executive Director, Head of Portfolio Planning, Ionis Pharmaceuticals, Inc. will help you hit the right notes in aligning short-term projects with long-term goals. It’s time to fine-tune your strategies and achieve that perfect balance. Register now to join this interactive discussion and keep your planning process in perfect pitch! https://lnkd.in/dmKigmrk #PPM #Boston #PlanningTunes #StrategicBalance #PharmaSuccess #Conference

Whilst we’re just past the halfway mark of 2024, mid-year analysis of the top selling drugs for the top 10 pharma companies provides some interesting insights into the demands of the market so far this year. Analysis from PharmaVoice shows that the leading drugs have generated over $55bn in revenue so far - just over 20% of the combined total revenue generated ($243.3bn) by the companies featured. More here👉 https://lnkd.in/eEhcqTnM

In the latest installment of our "Welcome to the Future" series, Managing Director of A&M’s Corporate Transactions Group (CTG) Marcos Cortes explores the impact of the Inflation Reduction Act (IRA) on pharmaceutical research and development (R&D). In an industry that invests a significant portion of its revenue in R&D, changes in drug pricing will undoubtedly influence future R&D budgets and strategies. Click to read more about Marcos's insights into Medicare drug negotiation under the IRA, its potential impact on the pharmaceutical industry, and its influence on future investment in innovation: https://okt.to/chfzkt #AlvarezandMarsal #CorporateTransactionsGroup #AMon J. Preston Parker, Jeff Wilson, Colin Harvey, Nancy T., Mat Hency, Kevin M., David Evans, Manish Gupta, Paul Aversano, Tom Elsenbrook, Anthony Caporrino, Xuong Liu, Fabio G. Pires, Jonathan Gibbons, Bhavik Hathi, Ashish Bansal, Philip Mitchell, Stella Yuan, Scott Foster, David Willis, Vivian Santora and Victoria Whitman

Our session yesterday, "Building Strategic Networks: Executive Edition", for a $15bn pharmaceutical company had a great discussion surrounding how to spark deeper conversations cross-functionally. The peer sharing was fabulous and really underscored the deep well of knowledge we all have in and around our teams. So let us tap into the collective knowledge we have in our LinkedIn community and share what questions you like to ask when reaching out to create a connection cross-functionally. #networking #peersharing #themoreyouknow

In this month’s edition of Logistics Manager Magazine, DHL Supply Chain's UKI CEO Saul Resnick discusses the logistics trends he’s expecting to see in 2024 (p15), while Dan Peacock, MD Life Sciences and Healthcare UKI, shares his insight into pharmaceutical supply chains (p19-20). Read what both Saul and Dan had to say here - https://okt.to/dwen4C #supplychain #2024Trends #lifesciencehealthcare

If you're attending the Expanded Access Programs World Congress next week in London, definitely find time to check out Ana Paula Tediosi's presentation, or catch her during the conference. Ana is a wealth of knowledge when it comes to end to end strategy for all types of access programs (among so many other things)! #earlyaccessprograms, #expandedaccess, #posttrialaccess, #compassionateuse, #clinicaltrials WEP Clinical

✔𝗕𝗿𝗶𝘀𝘁𝗼𝗹 𝗠𝘆𝗲𝗿𝘀 𝗦𝗾𝘂𝗶𝗯𝗯 𝗥𝗲𝗽𝗼𝗿𝘁𝘀 𝗠𝗶𝘅𝗲𝗱 𝗙𝗶𝗿𝘀𝘁-𝗤𝘂𝗮𝗿𝘁𝗲𝗿 𝗥𝗲𝘀𝘂𝗹𝘁𝘀 𝗔𝗺𝗶𝗱 𝗖𝗼𝘀𝘁-𝗖𝘂𝘁𝘁𝗶𝗻𝗴 𝗠𝗲𝗮𝘀𝘂𝗿𝗲𝘀 Bristol Myers Squibb, a prominent pharmaceutical company, unveiled its first-quarter financial results on Thursday, revealing revenue that surpassed expectation 𝗙𝗼𝗿 𝗺𝗼𝗿𝗲 𝗜𝗻𝗳𝗼𝗿𝗺𝗮𝘁𝗶𝗼𝗻 📕Read - https://lnkd.in/d_nUEG58 𝗮𝗻𝗱 𝗴𝗲𝘁 𝗜𝗻𝘀𝗶𝗴𝗵𝘁𝘀 #BristolMyersSquibb #QuarterlyResults #CostCutting #Pharmaceuticals #BusinessNews #Finance #Investing #EarningsReport #HealthcareSector #CorporateFinance #StockMarket #EconomicUpdate #FinancialNews #PharmaIndustry #CostManagement #BusinessPerformance #RevenueAnalysis #QuarterlyEarnings #InvestmentAnalysis

Download now: https://ow.ly/rLtO50Telc6 Exciting times ahead in the pharmaceutical industry! EVERSANA’s latest POV, “The Future of Global #Commercialization,” dives deep into how a unified, #data-driven, and #patient-centric approach is transforming the landscape. From innovative strategies to cutting-edge technologies, discover how we’re paving the way for a more efficient and effective healthcare system. Don’t miss out on these groundbreaking insights! #GlobalCommercialization #DataDriven #PatientCentric

We're thrilled to announce that Marko Matovic , our Legal & Compliance Director, participated in the #HEALTHPHARM 2024 conference, where the legal, compliance, pharmaceutical, and healthcare sectors intersected. This conference, a pioneering initiative in Southeast Europe, fostered dynamic debates and invaluable exchanges. Marko shared his insights among esteemed moderators, speakers, and panelists, contributing to discussions on the topic of "How to buy and sell health & pharma business?". Join us in exploring the latest trends and insights in healthcare industry! #HealthPharm2024 #LegalCompliance #IndustryInsights #LegalDebates #Zdravlje

Keir Milburn from Abundance (UK) proposes public-common partnership to build an alternative pharmaceutical infrastructure. 🏥  “It is Important is to have transparent finances, re-invested into the industry and not in the pockets of people who are already rich.”  Milburn makes clear that to move away from the current model, we will need a strategy. Now it is Big Pharma who has the resources and they put extra pressure by claiming that there is no alternative. But one by one, we can build a public-common network and we can achieve a democratic way of organizing the medicines production by putting our own demands. 🏥🔥 #Publicpharmaeurope